Acadia Pharmaceuticals (ACAD)

Company Description

ACADIA Pharmaceuticals (ACAD) focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead drug candidate is NUPLAZID, which has delivered positive data in Phase III pivotal trials with a pristine safety profile for the treatment of Parkinson’s disease psychosis, an unmet medical need.   The potential blockbuster is also in Phase II development for Alzheimer’s disease psychosis and is currently planning a Phase II trial for the treatment of schizophrenia. ACAD also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc.

 

COMPANY ADDRESS
3611 Valley Centre Drive; Suite 300
San Diego, CA 92130
United States

COMPANY PHONE
(858) 558-2871

COMPANY WEBSITE


Get BioInvest's perspective on Acadia's CEO

Latest Company News

Surveying Shares of ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD) Clayton News - 59 minutes ago ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD) has a Value Composite score of 93. Developed by James O'Shaughnessy, the VC score uses six valuation ratios. ACADIA Pharmaceuticals Inc. (ACAD) Position Boosted by PNC Financial Services ... - StockNewsTimes [...]
Sat, Aug 19, 2017 4:18:00 AM, Continue reading at the source
Two sizzlers stock's are not to be missed: ACADIA Pharmaceuticals Inc. (ACAD ... StockNewsJournal - Aug 17, 2017 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) market capitalization at present is $3.72B at the rate of $31.39 a share. The firm's price-to-sales ratio was noted 62.39 in contrast with an overall industry average of 81.42. [...]
Thu, Aug 17, 2017 1:52:00 PM, Continue reading at the source
Acadia Pharmaceuticals Has Huge Opportunities Ahead Investopedia - Aug 15, 2017 (Note: The author of this fundamental analysis is a financial writer and portfolio manager. He and his clients own shares of ACAD. Cowen Dives In on ACADIA Pharmaceuticals Inc. (ACAD) Following Meeting with ... - Smarter Analyst ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $41.09 Consensus Target ... - BNB Daily (blog) [...]
Tue, Aug 15, 2017 7:58:00 PM, Continue reading at the source
Which Way Traders Signposts PDL BioPharma, Inc. (PDLI), ACADIA Pharmaceuticals ... StockNewsJournal - Aug 14, 2017 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), maintained return on investment for the last twelve months at -74.14, higher than what Reuters data shows regarding industry's average. [...]
Mon, Aug 14, 2017 3:00:00 PM, Continue reading at the source
The Volatility Option Trade After Earnings in ACADIA Pharmaceuticals Inc CML News - Aug 10, 2017 For ACADIA Pharmaceuticals Inc, irrespective of whether the earnings move was up or down, if we waited one-day after the stock move, and then sold a one-week at out of the money iron condor (using weekly options), the results were quite strong. [...]
Thu, Aug 10, 2017 7:48:00 PM, Continue reading at the source
ACADIA Reports Strong Earnings Resulting From Accounting Change Seeking Alpha - Aug 10, 2017 ACADIA Pharmaceuticals (NASDAQ:ACAD), a biopharmaceutical company specializing in drugs for central nervous system disorders, recently announced their Q2 earnings report. ACADIA Pharmaceuticals Shares Surge Up On Better Than Expected Results - Investing.com Lookout for Price Target? ACADIA Pharmaceuticals Inc. (ACAD), CenturyLink, Inc ... - StockNewsJournal [...]
Thu, Aug 10, 2017 5:37:00 PM, Continue reading at the source
Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today Motley Fool - Aug 9, 2017 In response to Acadia Pharmaceuticals (NASDAQ:ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous system, were trading 13.9% higher as of 1:35 ... ACADIA Pharmaceuticals Inc. (ACAD) Nuplazid on a Roll, Marvels Cowen - Smarter Analyst Why Acadia Pharma Is One of Wednesday's Best Earnings Reports - 24/7 Wall St. [...]
Wed, Aug 09, 2017 5:37:00 PM, Continue reading at the source
NF Trinity Capital (Hong Kong) Ltd Buys ACADIA Pharmaceuticals Inc, NXP ... Nasdaq - Aug 9, 2017 NF Trinity Capital (Hong Kong) Ltd initiated holdings in ACADIA Pharmaceuticals Inc. The purchase prices were between $25.45 and $34.71, with an estimated average price of $29.9. [...]
Wed, Aug 09, 2017 8:26:00 AM, Continue reading at the source
ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results Business Wire (press release) - Aug 8, 2017 SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) ... ACADIA Pharmaceuticals' (ACAD) CEO Stephen Davis on Q2 2017 Results - Earnings ... - Seeking Alpha ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Files An 8-K Results of Operations ... - Market Exclusive [...]
Tue, Aug 08, 2017 8:03:00 PM, Continue reading at the source
ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on ... Business Wire (press release) - Aug 1, 2017 SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system ... ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Trading Volume Significantly Lower - First News 24 [...]
Tue, Aug 01, 2017 12:56:00 PM, Continue reading at the source